Try our mobile app

Switch to company model in classical logic    *

General information

Country: BRITAIN

Sector: Biotechnology

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company`s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Website: immunocore.com



Growth: Good revenue growth rate 15.9%, there is slowdown compared to average historical growth rates 95.5%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -12.3%. On average the margin is decreasing steadily. Gross margin is high, +99.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$9.83 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -22.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 37.7% higher than minimum and 55.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.5x by EV / Sales multiple , the company can be 3.8% undervalued

Insiders: For the last 3 months insiders sold company shares on $5.0 mln (-0.285% of cap.)

Key Financials (Download financials)

Ticker: IMCR
Share price, USD:  (0.0%)33.78
year average price 32.71  


year start price 30.23 2025-01-08

min close price 24.53 2025-04-08

max close price 40.22 2025-12-04

current price 33.78 2026-01-07
Common stocks: 43 897 101

Dividend Yield:  0.0%
Last revenue growth (y/y):  +15.9%
Last growth of EBITDA (y/y):  -42.1%
Historical revenue growth:  +95.5%
Historical growth of EBITDA:  +13.2%
EV / Sales: 4.3x
Margin (EBITDA LTM / Revenue): -12.3%
Fundamental value created in LTM:
Market Cap ($m): 1 483
Net Debt ($m): -57
EV (Enterprise Value): 1 426
Price to Book: 3.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-07seekingalpha.com

Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst

2025-09-10seekingalpha.com

Immunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-08-09seekingalpha.com

Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

2025-03-10globenewswire.com

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

2025-02-27seekingalpha.com

Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point

2025-02-19globenewswire.com

Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

2025-02-17zacks.com

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

2025-01-13zacks.com

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

2025-01-10globenewswire.com

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

2024-12-12zacks.com

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR
reportedCurrency USD USD USD USD USD USD GBP GBP GBP GBP GBP
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-11-07 2023-08-10 2023-03-01 2022-12-31 2022-11-18
acceptedDate 2025-11-06 07:00:59 2025-08-07 07:01:04 2024-11-06 07:00:49 2024-08-08 07:06:42 2024-05-08 07:00:48 2023-11-07 07:09:18 2023-11-07 07:09:18 2023-08-10 08:28:14 2023-03-01 08:06:28 2022-12-30 19:00:00 2022-11-18 16:17:11
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 104M 98M 80M 75M 71M 106M 51M 48M 45M 48M 41M
costOfRevenue 513 000 1M 448 000 2M 246 000 -247 000 220 000 886 000 178 000 109 000 63 000
grossProfit 103M 97M 80M 74M 70M 106M 51M 47M 44M 48M 41M
grossProfitRatio 0.995 0.989 0.994 0.977 0.997 1.002 0.996 0.981 0.996 0.998 0.998
researchAndDevelopmentExpenses 71M 69M 53M 51M 57M 75M 32M 29M 28M 27M 23M
generalAndAdministrativeExpenses 0 0 24M 26M 0 47M 11M 36M 0 0 18M
sellingAndMarketingExpenses 0 0 12M 13M 0 17M 0 0 0 0 7M
sellingGeneralAndAdministrativeExpenses 40M 43M 36M 39M 39M 57M 11M 36M 33M 43M 26M
otherExpenses 0 0 0 4M -190 000 0 0 0 0 -2000 964 000
operatingExpenses 110M 112M 88M 90M 97M 132M 43M 65M 62M 70M 50M
costAndExpenses 111M 113M 89M 91M 97M 132M 43M 66M 62M 70M 50M
interestIncome 4M 4M 6M 6M 8M 8M 4M 3M 3M 2M 597 000
interestExpense 3M 3M 4M 4M 3M 337 000 2M 2M 2M 3M 2M
depreciationAndAmortization 798 000 780 000 1M 992 000 1M 121 000 1M 1M 4M 2M 2M
ebitda 4M -6M 11M -16M -17M -19M 14M -13M -14M -20M -7M
ebitdaratio 0.04 -0.065 0.136 -0.065 -0.247 -0.177 0.273 -0.276 -0.304 -0.414 -0.168
operatingIncome -7M -15M -9M -16M -26M -26M -699 000 -16M -17M -22M -9M
operatingIncomeRatio -0.069 -0.152 -0.106 -0.212 -0.376 -0.244 -0.014 -0.33 -0.39 -0.465 -0.219
totalOtherIncomeExpensesNet 7M 5M 15M 6M -3M -14M -9M 2M 926 000 -748 000 14M
incomeBeforeTax 304 000 -10M 6M -10M -24M -32M 2M -14M -16M -23M 5M
incomeBeforeTaxRatio 0.003 -0.099 0.076 -0.134 -0.342 -0.305 0.034 -0.292 -0.37 -0.48 0.121
incomeTaxExpense -481 000 606 000 -3M 1M 357 000 -6M -144 000 151 000 236 000 2M -1M
netIncome 785 000 -10M 9M -12M -24M -26M 2M -14M -17M -25M 6M
netIncomeRatio 0.008 -0.105 0.109 -0.154 -0.347 -0.25 0.037 -0.295 -0.375 -0.524 0.151
eps 0.016 -0.21 0.17 -0.23 -0.49 -0.54 0.04 -0.29 -0.35 -0.54 0.13
epsdiluted 0.016 -0.21 0.17 -0.23 -0.49 -0.54 0.04 -0.29 -0.35 -0.54 0.12
weightedAverageShsOut 50M 50M 50M 50M 50M 49M 54M 49M 48M 47M 47M
weightedAverageShsOutDil 50M 50M 53M 50M 50M 49M 54M 49M 48M 47M 51M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR
reportedCurrency USD USD USD USD USD USD GBP GBP USD GBP GBP
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-11-07 2023-08-10 2023-03-01 2022-12-31 2022-09-30
acceptedDate 2025-11-06 07:00:59 2025-08-07 07:01:04 2024-11-06 07:00:49 2024-08-08 07:06:42 2024-05-08 07:00:48 2023-11-07 07:09:18 2023-11-07 07:09:18 2023-08-10 08:28:14 2023-03-01 08:06:28 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 498M 488M 538M 505M 833M 443M 364M 342M 337M 333M 347M
shortTermInvestments 394M 395M 364M 355M 0 0 0 0 0 0 0
cashAndShortTermInvestments 892M 883M 901M 860M 833M 443M 364M 342M 337M 333M 347M
netReceivables 76M 70M 64M 60M 58M 61M 50M 51M 48M 58M 55M
inventory 6M 5M 5M 3M 4M 5M 2M 2M 882 000 943 000 854 000
otherCurrentAssets 49M 44M 36M 34M 31M 10M 16M 19M 0 0 0
totalCurrentAssets 1 023M 1 002M 1 006M 957M 926M 529M 416M 395M 386M 392M 404M
propertyPlantEquipmentNet 49M 49M 49M 40M 41M 43M 34M 33M 33M 32M 31M
goodwill 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 2M 410 000 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 2M 410 000 410 000 410 000 0
longTermInvestments 0 0 0 0 0 0 0 0 7M 137 000 0
taxAssets 14M 14M 13M 10M 11M 11M 4M 4M 4M 4M 4M
otherNonCurrentAssets 16M 17M 17M 16M 16M 14M 9M 8M 0 7M 7M
totalNonCurrentAssets 80M 80M 79M 67M 68M 68M 48M 45M 45M 44M 41M
otherAssets 0 0 0 1 0 0 0 0 0 0 0
totalAssets 1 103M 1 082M 1 085M 1 023M 994M 597M 464M 440M 431M 436M 445M
accountPayables 23M 24M 20M 20M 16M 18M 11M 14M 9M 75M 10M
shortTermDebt 2M 2M 49M 1M 1M 1M 2M 3M 2M 2M 2M
taxPayables 0 0 962 000 992 000 6M 2M 2M 2M 2M 927 000 1M
deferredRevenue 582 000 594 000 0 5M 5M 0 2M 3M 5M 6M 11M
otherCurrentLiabilities 145M 144M 196M 163M 133M 120M 82M 73M 69M 51 000 54M
totalCurrentLiabilities 170M 170M 266M 185M 155M 139M 98M 92M 85M 83M 77M
longTermDebt 41M 435M 432M 472M 472M 83M 68M 65M 66M 68M 73M
deferredRevenueNonCurrent 0 5M 6M 5M 5M 6M 4M 4M 4M 4M 0
deferredTaxLiabilitiesNonCurrent 0 0 0 33M -443M 0 0 0 0 0 0
otherNonCurrentLiabilities 494M 84M 3M 2M 445M 978 000 3M 2M 949 000 2M 108 000
totalNonCurrentLiabilities 536M 524M 441M 479M 479M 89M 75M 71M 72M 74M 73M
otherLiabilities 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 0 44M 42M 35M 35M 36M 31M 29M 29M 30M 29M
totalLiabilities 706M 694M 707M 664M 634M 228M 173M 163M 156M 157M 150M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 135 000 135 000 135 000 136 000 135 000 135 000 99 000 98 000 97 000 97 000 96 000
retainedEarnings -801M -801M -772M -781M -769M -745M -290M -292M -278M -261M -236M
accumulatedOtherComprehensiveIncomeLoss -30M -27M -31M -34M -35M -36M 334M 336M 335M 335M 336M
othertotalStockholdersEquity 1 228M 1 216M 1 181M 1 174M 1 164M 1 150M 248M 233M 217M 205M 195M
totalStockholdersEquity 397M 388M 378M 359M 360M 369M 292M 277M 274M 279M 295M
totalEquity 397M 388M 378M 359M 360M 369M 292M 277M 274M 279M 295M
totalLiabilitiesAndStockholdersEquity 1 103M 1 082M 1 085M 1 023M 994M 597M 464M 440M 431M 436M 445M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 103M 1 082M 1 085M 1 023M 994M 597M 464M 440M 431M 436M 445M
totalInvestments 394M 395M 364M 355M 0 0 0 0 7M 137 000 0
totalDebt 43M 436M 481M 473M 473M 84M 70M 67M 68M 69M 74M
netDebt -455M -51M -57M -32M -360M -359M -294M -275M -269M -263M -273M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR IMCR
reportedCurrency USD USD USD USD USD GBP GBP GBP GBP GBP GBP
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-11-07 2023-08-10 2023-03-01 2022-12-31 2022-11-18
acceptedDate 2025-11-06 07:00:59 2025-08-07 07:01:04 2024-11-06 07:00:49 2024-08-08 07:06:42 2024-05-08 07:00:48 2023-11-07 07:09:18 2023-11-07 07:09:18 2023-08-10 08:28:14 2023-03-01 08:06:28 2022-12-30 19:00:00 2022-11-18 16:17:11
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -177 000 -10M 9M -12M -24M -26M 2M -14M -17M -25M 6M
depreciationAndAmortization 798 000 780 000 1M 992 000 1M 121 000 1M 1M 1M 1M 1M
deferredIncomeTax 0 0 0 0 0 2M -144 000 151 000 236 000 2M 0
stockBasedCompensation 10M 10M 7M 10M 9M 12M 7M 7M 7M 7M 6M
changeInWorkingCapital -1M 27M -35M 27M 8M -3M 5M 2M 3M 6M 7M
accountsReceivables -6M -4M -2M -3M -6M 0 -1M -6M 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -287 000 -7M -776 000 4M -2M 0 0 0 0 0 0
otherWorkingCapital 5M 38M -32M 25M 13M -3M 6M 8M 3M 6M 7M
otherNonCashItems -14M -1M 40M 1M 430 000 7M -9M 1M 15M 15M -12M
netCashProvidedByOperatingActivities -4M 26M 21M 23M -5M -9M 5M -2M 9M 6M 8M
investmentsInPropertyPlantAndEquipment -748 000 -414 000 -828 000 -331 000 -430 000 -471 000 -2M -768 000 -2M -1M -394 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 -30M 109 680 -350M 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 6M 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -109 680 -350M 0 -9M 4M 3M 2M 2M 597 000
netCashUsedForInvestingActivites 5M -30M -828 000 -350M -430 000 -10M 2M 3M -394 000 332 000 203 000
debtRepayment 0 0 0 0 -403M -1M -312 000 -398 000 -407 000 -44M -816 000
commonStockIssued 0 4M -303 182 303 182 0 0 0 0 0 -117M 117M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M -43 678 198 000 -818 000 -12M 19M 7M 8M 3M 160M 2M
netCashUsedProvidedByFinancingActivities 2M 4M 198 000 -818 000 396M 18M 6M 7M 2M -1M 118M
effectOfForexChangesOnCash 8M 12M 12M -159 000 -800 000 9M 8M -3M -6M -20M 13M
netChangeInCash 10M 11M 33M -328M 390M 79M 22M 5M 5M -15M 139M
cashAtEndOfPeriod 498M 488M 538M 505M 833M 443M 364M 342M 337M 333M 347M
cashAtBeginningOfPeriod 488M 477M 505M 833M 443M 364M 342M 337M 333M 347M 208M
operatingCashFlow -4M 26M 21M 23M -5M -9M 5M -2M 9M 6M 8M
capitalExpenditure -748 000 -414 000 -828 000 -331 000 -430 000 -471 000 -2M -768 000 -2M -1M -394 000
freeCashFlow -5M 26M 20M 23M -5M -9M 3M -3M 6M 5M 8M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q2
2025-08-09 ET (fiscal 2025 q2)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q2
2024-08-11 ET (fiscal 2024 q2)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q2
2022-08-10 ET (fiscal 2022 q2)

SEC forms

Show financial reports only

SEC form 8
2025-11-06 07:31 ET
Immunocore Holdings plc published news for 2025 q3
SEC form 8
2025-11-06 07:31 ET
Immunocore Holdings plc reported for 2025 q3
SEC form 10
2025-11-06 07:00 ET
Immunocore Holdings plc reported for 2025 q3
SEC form 8
2025-08-07 11:40 ET
Immunocore Holdings plc published news for 2025 q2
SEC form 8
2025-08-07 11:40 ET
Immunocore Holdings plc reported for 2025 q2
SEC form 10
2025-08-07 11:01 ET
Immunocore Holdings plc reported for 2025 q2
SEC form 8
2025-05-07 11:33 ET
Immunocore Holdings plc published news for 2025 q1
SEC form 8
2025-05-07 11:33 ET
Immunocore Holdings plc reported for 2025 q1
SEC form 10
2025-05-07 11:00 ET
Immunocore Holdings plc published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Immunocore Holdings plc published news for 2025 q1
SEC form 8
2025-03-17 12:18 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-03-17 12:18 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-03-17 12:18 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-03-17 12:18 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-03-10 20:17 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-03-10 20:17 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 10
2025-02-26 12:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 10
2025-02-26 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Immunocore Holdings plc reported for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Immunocore Holdings plc published news for 2024 q4
SEC form 8
2024-11-06 07:22 ET
Immunocore Holdings plc reported for 2024 q3
SEC form 8
2024-11-06 07:22 ET
Immunocore Holdings plc published news for 2024 q3
SEC form 10
2024-11-06 07:00 ET
Immunocore Holdings plc reported for 2024 q3
SEC form 8
2024-08-08 07:21 ET
Immunocore Holdings plc published news for 2024 q2
SEC form 8
2024-08-08 07:21 ET
Immunocore Holdings plc reported for 2024 q2
SEC form 10
2024-08-08 07:06 ET
Immunocore Holdings plc reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Immunocore Holdings plc reported for 2024 q2
SEC form 8
2024-05-08 07:13 ET
Immunocore Holdings plc reported for 2024 q1
SEC form 8
2024-05-08 07:13 ET
Immunocore Holdings plc published news for 2024 q1
SEC form 10
2024-05-08 07:00 ET
Immunocore Holdings plc reported for 2024 q1
SEC form 10
2024-05-08 00:00 ET
Immunocore Holdings plc reported for 2024 q1
SEC form 8
2024-02-28 16:19 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-02-28 16:19 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-02-28 16:19 ET
Immunocore Holdings plc reported for 2023 q4
SEC form 10
2024-02-28 07:33 ET
Immunocore Holdings plc reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Immunocore Holdings plc reported for 2023 q4
SEC form 8
2024-01-29 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-29 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-29 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
Immunocore Holdings plc published news for 2023 q4
SEC form 6
2023-11-07 07:09 ET
Immunocore Holdings plc reported for 2023 q3
SEC form 6
2023-08-10 08:28 ET
Immunocore Holdings plc reported for 2023 q2
SEC form 6
2023-07-14 16:21 ET
Immunocore Holdings plc published news for 2023 q2
SEC form 6
2023-06-05 09:20 ET
Immunocore Holdings plc published news for 2023 q1
SEC form 6
2023-04-18 16:15 ET
Immunocore Holdings plc published news for 2023 q1
SEC form 6
2023-04-18 16:13 ET
Immunocore Holdings plc published news for 2023 q1
SEC form 6
2023-03-10 07:00 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-03-02 08:15 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-03-01 09:13 ET
Immunocore Holdings plc reported for 2022 q4
SEC form 6
2023-03-01 08:06 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 20
2023-03-01 00:00 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-02-22 17:25 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-01-11 16:18 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2023-01-09 16:43 ET
Immunocore Holdings plc published news for 2022 q4
SEC form 6
2022-12-08 16:59 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-12-02 17:08 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-11-18 16:17 ET
Immunocore Holdings plc reported for 2022 q3
SEC form 6
2022-11-14 07:59 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-11-09 07:15 ET
Immunocore Holdings plc published news for 2022 q3
SEC form 6
2022-09-30 16:24 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-09-09 16:29 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-09-09 12:33 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-08-10 08:00 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-07-20 16:06 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-07-11 16:05 ET
Immunocore Holdings plc published news for 2022 q2
SEC form 6
2022-06-27 16:05 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-09 16:12 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-08 16:06 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-06 16:21 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-06-03 16:05 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-05-12 16:25 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-05-11 07:08 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-04-14 16:11 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-04-04 16:06 ET
Immunocore Holdings plc published news for 2022 q1
SEC form 6
2022-03-03 07:09 ET
Immunocore Holdings plc published news for 2021 q4
SEC form 6
2022-03-03 07:01 ET
Immunocore Holdings plc published news for 2021 q4
SEC form 20
2022-03-03 00:00 ET
Immunocore Holdings plc published news for 2021 q4
SEC form 6
2022-01-26 16:29 ET
Immunocore Holdings plc published news for 2021 q4
SEC form 6
2021-12-07 16:10 ET
Immunocore Holdings plc published news for 2021 q3
SEC form 6
2021-11-10 07:01 ET
Immunocore Holdings plc published news for 2021 q3
SEC form 6
2021-08-24 16:33 ET
Immunocore Holdings plc published news for 2021 q2
SEC form 6
2021-08-11 07:00 ET
Immunocore Holdings plc published news for 2021 q2
SEC form 6
2021-05-12 07:00 ET
Immunocore Holdings plc published news for 2021 q1
SEC form 6
2021-03-25 07:01 ET
Immunocore Holdings plc published news for 2020 q4